Article

Exploring real-world concordance of tissue mutation burden (TMB) from blood and tissue in patients with solid tumors

2021-05-13

Abstract excerpt

<h4>Purpose</h4> Tumor mutational burden (TMB) is an approved biomarker for immunotherapy in metastatic cancer patients. While initially measured from tissue (tTMB), TMB derived from circulating tumor DNA (ctDNA) - also known as blood TMB (bTMB) - is increasingly being used in the clinic. Currently, real-world concordance between tTMB and bTMB is not well understood. <h4>Patients and methods</h4> From October 2020...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9c38585a-4f3e-51e0-99ad-8c4d905a7375
DOI: 10.1101/2021.05.05.21256698

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Exploring real-world concordance of tissue mutation burden (TMB) from blood and tissue in patients with solid tumorsDOI 10.1101/2021.05.05.21256698Read

Higher Blood-to-Tissue Tumor Mutational Burden Ratio Is Associated With Poorer Overall Survival in Advanced Non-Small Cell Lung CancerSemantic proximity Read

Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings.Semantic proximity Read

Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden.Semantic proximity Read

Concurrent Tissue and Circulating Tumor DNA Molecular Profiling to Detect Guideline-Based Targeted Mutations in a Multicancer Cohort.Semantic proximity Read

Expert consensus on the detection and clinical application of tumor mutational burden.Semantic proximity Read

Validity and utility of blood tumor mutational burden (bTMB) is dependent on circulating tumor DNA (ctDNA) shed: SCRUM-Japan MONSTAR-SCREENSemantic proximity Read

Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC.Semantic proximity Read

A Review of Circulating Tumor DNA (ctDNA) and the Liquid Biopsy in Cancer Diagnosis, Screening, and Monitoring Treatment ResponseSemantic proximity Read

Measuring Tumor Mutational Burden (TMB) in Plasma from mCRPC Patients Using Two Commercial NGS AssaysSemantic proximity Read

Validity and utility of blood tumor mutational burden is dependent on circulating tumor DNA shedSemantic proximity Read

Influence of low tumor content on tumor mutational burden estimation by whole-exome sequencing and targeted panel sequencing.Semantic proximity Read

Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy.Semantic proximity Read